Aldeyra Therapeutics (ALDX) risk factors, FY2025 10-K

Other

1. 01Summary of Risks Related to our Business
2. 02We will require substantial additional financing, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our product development, other operations or commercialization efforts24% rewritten

Risks Related to the Potential Development and Commercialization of Reproxalap and our Product Candidates

1. 03we may not be able to obtain, maintain, or enforce our patents and other intellectual property rights60% rewritten
2. 04The FDA’s shift toward “radical transparency,” including plans to release future complete response letters promptly after they are issued to sponsors, could have an adverse impact on our business and adversely affect our commercial prospectsNew
3. 05delay or complicate ongoing regulatory interactions, particularly if deficiencies cited by the FDA are discussed publicly before resolutionNew
4. 06could be forced to delay, reduce, or eliminate our research and development programs and reproxalap commercialization effortsNew
5. 07If the AbbVie Option is exercised and the Collaboration Agreement is executed, then pursuant to the terms of the Collaboration Agreement, we would work closely with AbbVie to execute a commercialization plan for reproxalap in the United States, and the commercialization plan may never achieve desired outcomes
6. 08Any termination or suspension of, or delays in the commencement or completion of, our clinical trials could result in increased costs to us, delay or limit our ability to generate revenue, and adversely affect our commercial prospects
7. 09one or more IRBs refusing to approve, suspending, or terminating a clinical trial at an investigational site, precluding enrollment of additional subjects, or withdrawing approval of the trial
8. 10our prioritization of other indications or product candidates for advancement
9. 11the approval policies, standards, or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners’ clinical data or regulatory submissions insufficient for approval
10. 12Because the Company has no experience in commercializing pharmaceutical products, there is a limited amount of information about us upon which to evaluate our product candidates and business prospects
11. 13gain broad market acceptance for our product candidates
12. 14We may not be successful in our efforts to identify or discover additional potential product candidates, or our decisions to prioritize the development of certain product candidates over others may later prove wrongNew
13. 15potential product candidates may not be effective in treating their targeted diseasesNew
14. 16The results of preclinical studies and earlier clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval
15. 17Because some of our product candidates are, to our knowledge, new chemical entities, it is difficult to predict the time and cost of development and our ability to successfully complete clinical development of these product candidates and obtain the necessary regulatory approvals for commercialization23% rewritten
16. 18To preserve trial integrity, clinical data from the initial parts of adaptive clinical trials may not be disclosed
17. 19We may find it difficult to enroll patients in our clinical trials or identify patients during commercialization (if our products are approved by regulatory agencies) for product candidates addressing orphan or rare diseases
18. 20Any product candidate we or any of our future development partners advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent regulatory approval or commercialization or limit commercial potential
19. 21The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
20. 22Even if we receive regulatory approval for reproxalap or any other product candidate, we or are partners, if any, still may not be able to successfully commercialize, and the revenue that we generate from its sales, if any, could be limited
21. 23the willingness of patients to pay out-of-pocket in the absence of third-party coverage
22. 24If the market opportunities for reproxalap and our other product candidates are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenue may be adversely affected, and our business may suffer
23. 25Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably
24. 26neither experimental nor investigational
25. 27We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products
26. 28The manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, or numerous other factors49% rewritten
27. 29Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products76% rewritten
28. 30and the loss of sales, which could have a material adverse effect on our business, financial condition, and results of operationsNew
29. 31If we are unable to enter into agreements with third parties to market, sell, and distribute our product candidates, we may be unable to generate any revenue
30. 32The holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product
31. 33The UK’s regulatory legal framework provides for similar periods of protection, namely regulatory data protection, marketing protection and market exclusivity
32. 34The FDA’s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels; government shutdowns; ability to hire and retain key personnel; and statutory, regulatory, and policy changes46% rewritten
33. 35We face uncertainty regarding potential regulatory developments that may adversely affect our business
34. 36Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing and commercializing our products abroad and may limit our ability to generate revenue from product sales

Risks Related to our Financial Position and Capital Requirements

1. 37We have incurred significant operating losses since inception, and we expect to incur significant losses over the next several years. We may never become profitable or, if achieved, be able to sustain profitability64% rewritten
2. 38there are any third‑party challenges to our intellectual property portfolio, or the need arises to defend against intellectual property‑related claims
3. 39obtaining, maintaining, and protecting our intellectual property rights
4. 40We will require substantial additional financing, and a failure to obtain the necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts
5. 41the costs of obtaining, maintaining, and enforcing our patents and other intellectual property rights
6. 42Our quarterly operating results may fluctuate significantly
7. 43derivative instruments recorded at fair value
8. 44Raising additional capital may cause dilution to stockholders, restrict our operations, or require us to relinquish rights to its technologies or product candidates
9. 45We may allocate our cash, cash equivalents, and marketable securities in ways that you or other stockholders may not approve
10. 46The terms of our secured debt facility require us to meet certain operating covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business
11. 47Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be limited as a result of transactions involving our common stock
12. 48Changes in tax laws and the implementation of tax laws could adversely affect usNew
13. 49Governments may impose price controls, which may adversely affect our future profitability
14. 50Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
15. 51Global economic conditions may have an adverse effect on our business73% rewritten
16. 52If we engage in an acquisition, reorganization, or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders
17. 53the potential loss of key employees of acquired businesses

Risks Related to our Reliance on Third Parties

1. 54We rely and will continue to rely on outsourcing arrangements for many of our activities, including clinical development, commercial readiness preparations, and supply of reproxalap and our other product candidates
2. 55Some of our product candidates may be studied in clinical trials co-sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we have minimal or no control over the conduct of such trials
3. 56We rely completely on third parties to supply drug substance and manufacture drug product for our clinical trials and preclinical studies. We intend to rely on other third parties to produce commercial supplies of product candidates, and our dependence on third parties could adversely impact our business
4. 57We may not be successful in establishing and maintaining development, commercial, or other strategic partnerships, which could adversely affect our ability to develop and commercialize product candidates42% rewritten
5. 58We may not realize the benefits of our current or future strategic alliances
6. 59Our internal computer systems, or those of our development partners, third-party clinical research organizations, or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs48% rewritten
7. 60inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidate could be delayedNew
8. 61The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challengesNew

Risks Relating to Our Intellectual Property

1. 62Our success depends on our and our licensors' ability to protect our intellectual property and our proprietary technologies
2. 63countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates
3. 64Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
4. 65require us to enter into royalty or licensing agreements
5. 66Our issued patents could be found invalid or unenforceable if challenged in court
6. 67We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or acquire rights or technology, which could result in the loss of rights or technology that are material to our business
7. 68We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees, consultants, or agents have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers39% rewritten
8. 69If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed
9. 70If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
10. 71Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
11. 72We may not be able to protect our intellectual property rights throughout the world
12. 73We and the third parties with whom we work are increasingly utilizing social media tools as a means of communication both internally and externally, and noncompliance with applicable requirements, policies, or contracts due to social media use or negative posts or comments could have an adverse effect on our business

Risks Related to Employee Matters and Managing Growth

1. 74We are highly dependent on the services of our senior management team and certain key consultants
2. 75If we fail to attract and retain senior management, we may be unable to successfully develop or commercialize our product candidates
3. 76In order to commercialize the product candidates not subject to existing partnership agreements, we will need to substantially grow the size of our organization. We may encounter difficulties in managing our growth and expanding our operations successfully

Risks Related to Other Legal or Regulatory Matters

1. 77Our business is subject to political, economic, legal, and social risks, which could adversely affect our business
2. 78currency transfer and other restrictions and regulations that may limit our ability to sell certain products or repatriate profits to the United States
3. 79Any changes related to political, economic, legal, and social factors could adversely affect any business operations that we conduct outside the United States92% rewritten
4. 80disruptions of our business operations, reputational harm, loss of revenue or profits, loss of customers or sales, and other adverse business consequencesNew
5. 81Current and future legislation may increase the difficulty and cost for us to obtain regulatory and marketing approval of and commercialize our product candidates, alone or with others, and may affect the prices we may obtain47% rewritten
6. 82the availability of capital
7. 83state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts
8. 84If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties
9. 85If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of reproxalap or our other product candidates
10. 86a decline in our stock price
11. 87We and our development partners, third-party manufacturers, and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage, or disposal of these materials could be time consuming or costly
12. 88We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business
13. 89penalties, or other remedial measures and legal expenses, any of which could adversely affect our business, results of operations and financial condition
14. 90Our employees, independent contractors, vendors, principal investigators, contract research organizations (CROs), and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards, regulatory requirements, and insider trading
15. 91failures to report financial information or data accurately
16. 92We are subject to litigation risks
17. 93We have been, are, and could in the future be, subject to securities class action litigation36% rewritten
18. 94Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities
19. 95U.S. federal and state income tax reform could adversely affect us

Risks Related to Our Common Stock

1. 96In the absence of an active trading market for our common stock, investors may not be able to resell their shares at or above the price at which the shares were purchased
2. 97The trading price of the shares of our common stock has been and is likely to continue to be highly volatile, and purchasers of our common stock could incur substantial losses
3. 98intellectual property, product liability, or other litigation against us
4. 99Short sellers may be manipulative and may drive down the market price of our common sharesNew
5. 100Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock
6. 101Because a small number of our existing stockholders own a substantial percentage of our outstanding common stock, your ability to influence corporate matters will be limited
7. 102If our shares become subject to the penny stock rules, it would become more difficult to trade our shares
8. 103We do not intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
9. 104A substantial number of shares of our common stock could be sold into the public market in the near future, which could depress our stock price
10. 105We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors
11. 106We are incurring significant increased costs and demands upon management as a result of operating as a public company
12. 107If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our common stock
13. 108If we are unable to establish and maintain effective internal controls it could have a material adverse effect on our business, financial condition, results of operations, or cash flows
14. 109If securities or industry analysts do not continue to publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
15. 110Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
16. 111establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings
17. 112Our business could be negatively affected as a result of the actions of activist stockholders